Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
- PMID: 16115318
- PMCID: PMC1232869
- DOI: 10.1186/1743-422X-2-69
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
Abstract
Background: Severe acute respiratory syndrome (SARS) is caused by a newly discovered coronavirus (SARS-CoV). No effective prophylactic or post-exposure therapy is currently available.
Results: We report, however, that chloroquine has strong antiviral effects on SARS-CoV infection of primate cells. These inhibitory effects are observed when the cells are treated with the drug either before or after exposure to the virus, suggesting both prophylactic and therapeutic advantage. In addition to the well-known functions of chloroquine such as elevations of endosomal pH, the drug appears to interfere with terminal glycosylation of the cellular receptor, angiotensin-converting enzyme 2. This may negatively influence the virus-receptor binding and abrogate the infection, with further ramifications by the elevation of vesicular pH, resulting in the inhibition of infection and spread of SARS CoV at clinically admissible concentrations.
Conclusion: Chloroquine is effective in preventing the spread of SARS CoV in cell culture. Favorable inhibition of virus spread was observed when the cells were either treated with chloroquine prior to or after SARS CoV infection. In addition, the indirect immunofluorescence assay described herein represents a simple and rapid method for screening SARS-CoV antiviral compounds.
Figures
Similar articles
-
Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies.Antivir Ther. 2007;12(4 Pt B):639-50. Antivir Ther. 2007. PMID: 17944271 Review.
-
Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2.J Virol. 2010 Dec;84(24):12658-64. doi: 10.1128/JVI.01542-10. Epub 2010 Oct 6. J Virol. 2010. PMID: 20926566 Free PMC article.
-
Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction.Antiviral Res. 2007 May;74(2):92-101. doi: 10.1016/j.antiviral.2006.04.014. Epub 2006 May 15. Antiviral Res. 2007. PMID: 16730806 Free PMC article.
-
Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor.Virology. 2006 Jun 20;350(1):15-25. doi: 10.1016/j.virol.2006.01.029. Epub 2006 Feb 28. Virology. 2006. PMID: 16510163 Free PMC article.
-
The spike protein of SARS-CoV--a target for vaccine and therapeutic development.Nat Rev Microbiol. 2009 Mar;7(3):226-36. doi: 10.1038/nrmicro2090. Epub 2009 Feb 9. Nat Rev Microbiol. 2009. PMID: 19198616 Free PMC article. Review.
Cited by
-
Efficacy of Ivermectin, Chloroquine/Hydroxychloroquine, and Azithromycin in Managing COVID-19: A Systematic Review of Phase III Clinical Trials.Biomedicines. 2024 Sep 27;12(10):2206. doi: 10.3390/biomedicines12102206. Biomedicines. 2024. PMID: 39457519 Free PMC article. Review.
-
N-alkylation of amines for the synthesis of potential antiviral agents: A structural modification approach.Heliyon. 2024 Sep 27;10(19):e38587. doi: 10.1016/j.heliyon.2024.e38587. eCollection 2024 Oct 15. Heliyon. 2024. PMID: 39397970 Free PMC article.
-
Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial.PLoS Med. 2024 Sep 12;21(9):e1004428. doi: 10.1371/journal.pmed.1004428. eCollection 2024 Sep. PLoS Med. 2024. PMID: 39264960 Free PMC article. Clinical Trial.
-
Unlocking insights: Navigating COVID-19 challenges and Emulating future pandemic Resilience strategies with strengthening natural immunity.Heliyon. 2024 Jul 17;10(15):e34691. doi: 10.1016/j.heliyon.2024.e34691. eCollection 2024 Aug 15. Heliyon. 2024. PMID: 39166024 Free PMC article. Review.
-
Identification of lysosomotropism using explainable machine learning and morphological profiling cell painting data.RSC Med Chem. 2024 May 24;15(8):2677-2691. doi: 10.1039/d4md00107a. eCollection 2024 Aug 14. RSC Med Chem. 2024. PMID: 39149097 Free PMC article.
References
-
- Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, Tong S, Urbani C, Comer JA, Lim W, Rollin PE, Dowell SF, Ling AE, Humphrey CD, Shieh WJ, Guarner J, Paddock CD, Rota PB, Fields B, DeRisi J, Yang JY, Cox N, Hughes J, LeDuc JW, Bellini WJ, Anderson LJ, SARS Working Group A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348:1953–1966. doi: 10.1056/NEJMoa030781. - DOI - PubMed
-
- Marra MA, Jones SJ, Astell CR, Holt RA, Brooks-Wilson A, Butterfield YS, Khattra J, Asano JK, Barber SA, Chan SY, Cloutier A, Coughlin SM, Freeman D, Girn N, Griffith OL, Leach SR, Mayo , McDonald H, Montgomery SB, Pandoh PK, Petrescu AS, Robertson AG, Schein JE, Siddiqui A, Smailus DE, Stott JM, Yang GS, Plummer F, Andonov A, Artsob H, Bastien N, Bernard K, Booth TF, Bowness D, Czub M, Drebot M, Fernando L, Flick R, Garbutt M, Gray M, Grolla A, Jones S, Feldmann H, Meyers A, Kabani A, Li Y, Normand S, Stroher U, Tipples GA, Tyler S, Vogrig R, Ward D, Watson B, Brunham RC, Krajden M, Petric M, Skowronski DM, Upton C, Roper RL. The Genome sequence of the SARS-associated coronavirus. Science. 2003;300:1399–1404. doi: 10.1126/science.1085953. - DOI - PubMed
-
- Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, Penaranda S, Bankamp B, Maher K, Chen MH, Tong S, Tamin A, Lowe L, Frace M, DeRisi JL, Chen Q, Wang D, Erdman DD, Peret TC, Burns C, Ksiazek TG, Rollin PE, Sanchez A, Liffick S, Holloway B, Limor J, McCaustland K, Olsen Rasmussen M, Fouchier R, Gunther S, Osterhaus AS, Drosten C, Pallansch MA, Anderson LJ, Bellini WJ. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science. 2003;300:1394–1399. doi: 10.1126/science.1085952. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous